Oncology Pipeline

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

KRAS G12C Inhibitor

LY3537982

Type of Alteration(s)

Point mutation

Alteration(s) of Interest

KRAS G12C

Methodology

Key Considerations

NGS (Tissue)

Suitable for broad-based genomic profiling that includes targets in addition to KRAS

PCR-based

Will detect selected mutations but may miss novel KRAS alterations
Selected assay should have full coverage of exon 2

NGS (cfDNA)

Useful when tissue biopsy sample is limited/unavailable
Higher false negative rate than tissue-based NGS testing

References

1. Sherwood JL et al, Esmo Open 2017;2(4) 2. Arbour et al. Clin Cancer Res 2021;27(8)

Check Clinical Trials information to see if patient qualifies

Need additional information or have a question:

Medical Science Liaison Request

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.